American Journal of Medicine最新文献

{"title":"New Clinical and Public Health Challenges in Vaccinations in US Adults.","authors":"John Dunn, Barry R Davis, Alexandra Matarazzo, Yanna Willett, Sadine Al-Farauki, Dennis G Maki, Charles H Hennekens","doi":"10.1016/j.amjmed.2024.09.025","DOIUrl":"10.1016/j.amjmed.2024.09.025","url":null,"abstract":"<p><p>During the past decade, growing recidivism has threatened the enormous beneficial impacts of vaccinations in the United States. The barriers are multifactorial and include increasing vaccine hesitancy. The continuing dedicated efforts of all healthcare professionals, along with advancements in vaccine technology and the resilience of public health systems, offers promise for the future. The ultimate goals of eradication and elimination of infectious diseases are within reach. The sustained commitments and collaborations of dedicated and conscientious individual healthcare providers and public health officials are important components. Healthcare providers and public health officials should remain cognizant that increasing vaccination rates are essential but not sufficient. Surveillance containment entails rapid detection and reporting of cases with prompt immunization of household members and close contacts of confirmed cases, combined with judicious use of isolation, prompt antiviral or antibiotic medications, social distancing, respiratory etiquette, home or large-scale quarantines, and masking. The continuing and expanded efforts of US healthcare providers are vital to these successes.</p>","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographical and Regional Trends of HIV-Related Mortality Among Young Adults in the United States From 1999 to 2020.","authors":"Kaneez Fatima, Amna Siddiqui, Ghulam Mustafa Ali Malik, Areeba Farooqui, Zuha Rasul, Faba Hanif, Bisma Mansoor, Fatima Mansoor, Mohammad Bilal Abbasi, Khizar Rehan, Rahima Azam, Aaliyan Wajid, Atida Awan, Ishaque Hameed","doi":"10.1016/j.amjmed.2024.09.026","DOIUrl":"10.1016/j.amjmed.2024.09.026","url":null,"abstract":"<p><strong>Background: </strong>HIV remains a leading cause of death in the U.S. Previous research has examined mortality patterns among older adults with HIV, revealing regional and demographic disparities. This study aims to assess demographic and regional trends in HIV-related mortality among young adults from 1999 to 2020.</p><p><strong>Methods: </strong>Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database was used to identify young adults aged 15-44 where HIV was mentioned as either underlying or contributory cause of mortality between 1999 and 2020, using the B20-B24 codes from the International Statistical Classification of Diseases and Related Health Problems-10th Revision (ICD-10). Age-adjusted mortality rates (AAMRs) per 100,000 population and annual percentage change (APC) were determined.</p><p><strong>Results: </strong>The AAMRs for HIV in young adults consistently declined from 1999 to 2018, followed by a period of stability from 2018 to 2020 (annual percentage change: 0.5%; 95% confidence interval [95% CI], -7.4 to 9.0), with 64% deaths occurred in medical facilities. Overall, males had a twice AAMR than females (female: 2.22, 95% CI 2.19-2.24; male: 5.19, 95% CI 5.15-5.23). Non-Hispanic (NH) Blacks had sevenfold higher mortality rates than Whites (AAMR 14.88 vs. 2.036). The Southern region experienced threefold higher mortality compared to the Midwest. Metropolitan adults had a twofold higher AAMR than nonmetropolitan adults. States in the top 90th percentile for HIV-related mortality, including Mississippi, Maryland, Florida, Louisiana, and the District of Columbia, exhibited six times higher mortality compared to states in the bottom 10th percentile, such as North Dakota, Idaho, Wyoming, Montana, and Utah.</p><p><strong>Conclusions: </strong>To address these disparities and ensure continued progress, urgent measures are required.</p>","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Complementary Medicine Among US Adults with Post-COVID-19: Results from the 2022 National Health Interview Survey.","authors":"Mirela Bilc, Holger Cramer","doi":"10.1016/j.amjmed.2024.09.023","DOIUrl":"10.1016/j.amjmed.2024.09.023","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to investigate the prevalence and type of complementary medicine (CM) use as well as potential factors related to CM use in a representative sample of US adults with self-reported post-COVID-19.</p><p><strong>Methods: </strong>This secondary data analysis was based on data from the 2022 National Health Interview Survey 2022 about presence of post-COVID-19 symptoms and CM use in a representative adult sample (weighted n = 89,437,918).</p><p><strong>Results: </strong>Our estimates indicate that 19.7% of those who reported having a symptomatic SARS-CoV-2 infection experienced post-COVID-19 symptoms, and 46.2% of those reported using any type of CM in the last 12 months. Specifically, post-COVID-19 respondents most often used mind-body medicine (32.0%), followed by massage (16.1%), chiropractic (14.4%), acupuncture (3.4%), naturopathy (2.2%), and art or music therapy (2.1%). Reporting post-COVID-19 was associated with an increased likelihood of using any CM in the last 12 months (adjusted odds ratio [AOR] 1.18; 95% confidence interval [CI]. 1.03-1.34; P = .014) and specifically, to visit an art or music therapist (AOR 2.56; 95% CI, 1.58-4.41; P < .001). The overall use of any CM was more likely among post-COVID-19 respondents under 65 years old, females, those with an ethnic background other than Hispanic, African-American, Asian, or non-Hispanic Whites, having a higher educational level, living in large metropolitan areas, and having private health insurance.</p><p><strong>Conclusions: </strong>Our findings show a high prevalence of CM use among post-COVID-19 respondents, which highlights the need for further investigations on effectiveness, safety, and possible mechanisms of action.</p>","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Red Lunulae, White Nails, and Cirrhosis.","authors":"Yasuhiro Kano","doi":"10.1016/j.amjmed.2024.09.021","DOIUrl":"10.1016/j.amjmed.2024.09.021","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chlorthalidone as Secondary Treatment in HFpEF?","authors":"Daniel M Gelfman","doi":"10.1016/j.amjmed.2024.09.027","DOIUrl":"10.1016/j.amjmed.2024.09.027","url":null,"abstract":"<p><p>This review addresses important issues that face practitioners today concerning the treatment of heart failure with preserved ejection fraction (HFpEF). It points out how the accepted efficacy of HFpEF medication treatment has changed. Medications are now recommended for use in HFpEF that have diuretic properties and are significant because of a reduction in the frequency of the development of heart failure (not mortality). This heart failure incidence reduction appears predictable and is valuable, but it raises the question of the use of chlorthalidone in the treatment of HFpEF. Chlorthalidone has previously been demonstrated to reduce heart failure incidence in the treatment of hypertensive patients, which is a similar patient population. Chlorthalidone, possibly with a generic mineralocorticoid antagonist, could be an acceptable low-cost alternate therapy as secondary treatment for HFpEF. Of course, chlorthalidone does not have the other theoretic benefits of the sodium-glucose cotransporter 2 (SGLT2) inhibitors or finerenone. It would be helpful if this was discussed in the upcoming HFpEF guidelines, especially for use in patients who cannot afford or tolerate the new HFpEF medications.</p>","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital Cutaneous Horn.","authors":"Thomas C Michels","doi":"10.1016/j.amjmed.2024.09.024","DOIUrl":"10.1016/j.amjmed.2024.09.024","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spontaneous Necrosis of Hepatocellular Carcinoma.","authors":"Taiki Mori, Hisashi Kametaka","doi":"10.1016/j.amjmed.2024.09.016","DOIUrl":"10.1016/j.amjmed.2024.09.016","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Febuxostat leads to better cardiovascular outcomes compared to allopurinol in patients with advanced chronic kidney disease: A Population-based Cohort Study.","authors":"Ming-Hsien Tsai, Yun-Yi Chen, Hung-Hsiang Liou, Jing-Tong Wang, Yu-Wei Fang","doi":"10.1016/j.amjmed.2024.09.018","DOIUrl":"https://doi.org/10.1016/j.amjmed.2024.09.018","url":null,"abstract":"<p><strong>Objective: </strong>Hyperuricemia is a risk factor for cardiovascular disease complications in patients with chronic kidney disease. The impact of febuxostat on cardiovascular disease in advanced chronic kidney disease remains unclear. This study aimed to explore the cardiovascular benefits of xanthine oxidase inhibitors, particularly febuxostat and allopurinol, in patients with advanced chronic kidney disease.</p><p><strong>Methods: </strong>A retrospective population-based cohort study was conducted using data from Taiwan's National Health Insurance Research Database (NHIRD) (2006-2017). The TriNetX dataset served as an external validation dataset. The study involved 13,187 patients with advanced chronic kidney disease treated with febuxostat or allopurinol. After propensity score matching, a balanced cohort of 976 patients (488 in each arm) was created. Hazard ratios (HRs) were calculated for all-cause mortality and hospitalizations, utilizing the competing risk regression model.</p><p><strong>Results: </strong>Febuxostat was associated with lower all-cause mortality (HR, 0.79; 95% confidence interval [CI], 0.64-0.98) and fewer hospitalizations (HR, 0.53; 95% CI, 0.44-0.63) than allopurinol. After adjustments, febuxostat also reduced hospitalizations for heart failure (HR, 0.59; 95% CI, 0.43-0.80) and infection (HR, 0.65; 95% CI, 0.52-0.82). This cardiovascular benefit of febuxostat was consistently observed in the TriNetX dataset. Moreover, subgroup analysis revealed that febuxostat was better in reducing death and heart failure events than allopurinol across most of the subgroups.</p><p><strong>Conclusions: </strong>Febuxostat may confer cardioprotective effects in patients with advanced chronic kidney disease compared with allopurinol, thereby potentially useful in reducing cardiovascular risks in this high-risk population.</p>","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Reply","authors":"Yasuhiro Kano MD ,&nbsp;Junko Araki MD, PhD","doi":"10.1016/j.amjmed.2024.06.011","DOIUrl":"10.1016/j.amjmed.2024.06.011","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142318856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Data Concerns in Myocardial Infarction with Right Bundle Branch Block Study: A Closer Look at Methodological Issues","authors":"José Nunes de Alencar MD","doi":"10.1016/j.amjmed.2024.05.004","DOIUrl":"10.1016/j.amjmed.2024.05.004","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142318857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}